dipeptidyl

Both pills work by inhibiting an enzyme called dipeptidyl peptidase 4 DPP-IV, which breaks down hormones that help control blood sugar.

Merck, Novartis Square Off In Diabetes DuelDiabetes Duel 2006

It was not until the mid-1990s that researchers saw another way: An enzyme called dipeptidyl peptidase four DPP4 broke down GLP, and by inhibiting it, researchers could boost GLP levels in the body.

Merck Starts Diabetes Race 2006

Osborne, who expects FDA approval of Novartis' Galvus in the first quarter, is one of a handful of analysts who believe Byetta will see significant competition from a new class of diabetes treatments known as dipeptidyl peptidase inhibitors.

Amylin Gets Euro OK For Byetta, Shares Fall 2006

Those results, as well as data on a class of drugs known as dipeptidyl peptidase IV inhibitors DPIV, could provide a catalyst for OSI shares, the Wachovia analyst said.

OSI's Macugen Still Burdened By Lucentis Threat 2006

Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors and is licensed as an adjunct to diet and exercise for the treatment of type 2 diabetes in combination with either metformin and/or a sulphonylurea, or in combination with metformin and/or a PPARy agonist, when the other agent (s) do not provide adequate glycaemic control.

Medlogs - Recent stories 2009

Onglyza, manufactured by Bristol-Myers Squibb of Princeton, N.J., is in a class of drugs known as dipeptidyl peptidase-4 inhibitors, which stimulate the pancreas to make more insulin.

Latest News - UPI.com 2009

Recent comments by Dr. Daniel Drucker, a professor at the University of Toronto and leader in diabetes and endocrinology, suggested dipeptidyl peptidase agents such as those being developed by Merck and Novartis have potential as effective second-line treatments for type 2 diabetes, according to Morgan Stanley.

Merck's Januvia Has 'Huge' Commercial Potential For Diabetes 2006

We also now have a library of dipeptidyl-peptidase IV DPP-4 inhibitors that we

unknown title 2011

Alogliptin is a dipeptidyl peptidase IV or DPP-4 inhibitor being investigated as an adjunct to diet and exercise for the treatment of Type 2 diabetes.

unknown title 2011

In the preclinical "db/db" model, in which the insulin response to oral glucose (sugar) is muted, oral GLP1R PAM facilitated an insulin response and better control over blood glucose than vehicle or a marketed drug to treat type II diabetes, sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.

Reuters: Press Release 2011